Kathleen I. Pritchard

Sunnybrook Health Science Centre — Canada

Biochemistry, Genetics and Molecular Biology · Life Sciences

99h-index59.5kcitations614works6.72yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Breast Cancer Treatment Studies(259), Estrogen and related hormone effects(163), Cancer Treatment and Pharmacology(151), Advanced Breast Cancer Therapies(127), HER2/EGFR in Cancer Research(118)

Publications613 total

Prognostic value of patient‐reported depression in women with hormone‐responsive early breast cancer in TEXT and SOFT
Cancer·2025
Extending the duration of endocrine treatment for early breast cancer: patient-level meta-analysis of 12 randomised trials of aromatase inhibitors in 22 031 postmenopausal women already treated with at least 5 years of endocrine therapy
The Lancet·2025· 13 citedOpen Access
Implementing routine collection of EQ-5D-5L in a breast cancer outpatient clinic
PLoS ONE·2024· 7 citedOpen Access
Anthracycline-containing and taxane-containing chemotherapy for early-stage operable breast cancer: a patient-level meta-analysis of 100 000 women from 86 randomised trials
The Lancet·2023· 169 citedOpen Access
Supplementary Data from Preferential Killing of Breast Tumor Initiating Cells by <i>N,N</i>-Diethyl-2-[4-(Phenylmethyl)Phenoxy]Ethanamine/Tesmilifene
2023Open Access
Supplementary Figure S3 from Predictive Significance of an Optimized Panel for Basal-like Breast Cancer: Results from the Canadian Cancer Trials Group MA.5 and MA.12 Phase III Clinical Trials
2023Open Access
Supplementary Figure 1 from Responsiveness of Intrinsic Subtypes to Adjuvant Anthracycline Substitution in the NCIC.CTG MA.5 Randomized Trial
2023Open Access
Data from Predictive Significance of an Optimized Panel for Basal-like Breast Cancer: Results from the Canadian Cancer Trials Group MA.5 and MA.12 Phase III Clinical Trials
2023Open Access
Supplementary Tables 1-2 from Responsiveness of Intrinsic Subtypes to Adjuvant Anthracycline Substitution in the NCIC.CTG MA.5 Randomized Trial
2023Open Access
Supplementary Figure S4 from Genetic Polymorphisms in the Long Noncoding RNA MIR2052HG Offer a Pharmacogenomic Basis for the Response of Breast Cancer Patients to Aromatase Inhibitor Therapy
2023Open Access
Supplementary Figures 1-2 from A 50-Gene Intrinsic Subtype Classifier for Prognosis and Prediction of Benefit from Adjuvant Tamoxifen
2023Open Access
Supplementary Figure 2 from Responsiveness of Intrinsic Subtypes to Adjuvant Anthracycline Substitution in the NCIC.CTG MA.5 Randomized Trial
2023Open Access
Supplementary Figure S5 from Genetic Polymorphisms in the Long Noncoding RNA MIR2052HG Offer a Pharmacogenomic Basis for the Response of Breast Cancer Patients to Aromatase Inhibitor Therapy
2023Open Access
Supplementary Figure S2 from Predictive Significance of an Optimized Panel for Basal-like Breast Cancer: Results from the Canadian Cancer Trials Group MA.5 and MA.12 Phase III Clinical Trials
2023Open Access
Supplementary Figure S6 from Genetic Polymorphisms in the Long Noncoding RNA MIR2052HG Offer a Pharmacogenomic Basis for the Response of Breast Cancer Patients to Aromatase Inhibitor Therapy
2023Open Access
Supplementary Material from Genetic Polymorphisms in the Long Noncoding RNA MIR2052HG Offer a Pharmacogenomic Basis for the Response of Breast Cancer Patients to Aromatase Inhibitor Therapy
2023Open Access
Supplementary Figure 1 from Responsiveness of Intrinsic Subtypes to Adjuvant Anthracycline Substitution in the NCIC.CTG MA.5 Randomized Trial
2023Open Access
Supplementary Figure S6 from Genetic Polymorphisms in the Long Noncoding RNA MIR2052HG Offer a Pharmacogenomic Basis for the Response of Breast Cancer Patients to Aromatase Inhibitor Therapy
2023Open Access
Supplementary Figure S3 from Genetic Polymorphisms in the Long Noncoding RNA MIR2052HG Offer a Pharmacogenomic Basis for the Response of Breast Cancer Patients to Aromatase Inhibitor Therapy
2023Open Access
Data from A 50-Gene Intrinsic Subtype Classifier for Prognosis and Prediction of Benefit from Adjuvant Tamoxifen
2023Open Access
page 1 of 31Next →

Frequent Co-authors

Martine Piccart(15), Timothy J. Whelan(13), James N. Ingle(12), Lois E. Shepherd(11), Mark N. Levine(10), Richard D. Gelber(9), Pamela J. Goodwin(9), Dongsheng Tu(9), Kathy S. Albain(8), Michael Gnant(8), Edith A. Perez(8), Eric P. Winer(7), Nancy E. Davidson(7), Daniel F. Hayes(7), Clifford A. Hudis(7), José Baselga(7), Hyman B. Muss(7), Aron Goldhirsch(6), Jonas Bergh(6), Gabriel N. Hortobágyi(6)